InsideArbitrage Potential Deal Alert: Biotech Cytokinetics (CYTK) Weighs Options After Receiving Takeover Interest

POTENTIAL DEAL DETAILS

According to Bloomberg, Cytokinetics (CYTK), a late-stage biotech firm developing cardiovascular treatments, is exploring options after receiving takeover interest.

Cytokinetics Investor Relations

Update(s):

January 8, 2024: According to WSJ, Novartis (NOVN) is close to clinching an acquisition of Cytokinetics (CYTK).

January 11, 2024: According to Reuters, Novartis has backed away from its pursuit of Cytokinetics (CYTK).

February 13, 2024: At the Oppenheimer conference, CEO Robert Blum said the company is not conducting a sales process.

June 5, 2024: Cytokinetics (CYTK) announced that in 2023, Cytokinetics discussed potential partnerships with several third-party companies. One of these companies expressed interest in buying Cytokinetics, which was negotiated in good faith and the company’s board was supportive of the potential acquisition, but the third-party company ultimately decided not to proceed.

Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.